GSTM1 and venous thromboembolism: However, the use of ESAs and HIF-prolyl hydroxylase inhibitors requires regular Hb monitoring to avoid the potential risks of stroke, cardiovascular events, venous thromboembolism, and hypertension associated with normalisation of Hb [4].